AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1.-7. Canceled.
- 8. (Previously Presented) A method of treating an inflammatory and/or autoimmune pathology induced by inflammatory cytokines, which method comprises administering to a patent in need of same an effective amount of a 2-aminotetraline of the formula (I)

$$R$$
 R
 NH_2
 (I)

or a pharmacologically acceptable salt of the formula (II)

FANTO et al Appl. No. 09/816,317 June 24, 2004

$$R \xrightarrow{R_2} (II)$$

$$R_1 \xrightarrow{NH_3^{\dagger}X_1}$$

wherein:

R and R_1 are independently halogen, hydroxy, or C_1 - C_4 alkoxy optionally substituted in position ω with a group selected from OH, NH₂ or NR₃R₄, wherein R₃ and R₄ are independently H, C_1 - C_4 alkyl, unsubstituted or substituted in position ω with groups OH, NH₂, C_1 - C_4 alkanoyl, C_1 - C_4 alkyl, carbamoyl, carbamoyloxy, amino, or amino-substituted NR₃R₄, where R₃ and R₄ have the above meanings,

 R_2 is hydrogen, halogen, hydroxy or methoxy, with the proviso that the 2-aminotetraline excludes (a) $R=R_1=CH_3O$ or OH, $R_2=H$, (b) R=F, $R_1=CH_3O$ or OH, $R_2=H$, (c) $R_1=-OCH_3$, $R=CH_3$ and $R_2=H$, or (d) $R=R_1=R_2=CH_3O$,

and X is the monovalent anion of a pharmacologically acceptable acid.

9. (Previously Presented) A method of preventing or treating septic shock comprising administering to a patient in need of same an effective amount of a 2-aminotetraline of the formula (I)

$$\begin{array}{c}
R_{2} \\
R_{1}
\end{array}$$

$$\begin{array}{c}
R_{2} \\
NH_{2}
\end{array}$$
(I)

or a pharmacologically acceptable salt of the formula (II)

$$R \xrightarrow{R_2} R$$

$$R_1 \xrightarrow{NH_3^+X^-} (II)$$

wherein:

R and R_1 are independently halogen, hydroxy, or C_1 - C_4 alkoxy optionally substituted in position ω with a group selected from OH, NH₂ or NR₃R₄, wherein R₃ and

FANTO et al Appl. No. 09/816,317 June 24, 2004

 R_4 are independently H, C_1 - C_4 alkyl, unsubstituted or substituted in position ω with groups OH, NH₂, C_1 - C_4 alkanoyl, C_1 - C_4 alkyl, carbamoyl, carbamoyloxy, amino, or amino-substituted NR₃R₄, where R₃ and R₄ have the above meanings,

R₂ is hydrogen, halogen, hydroxy or methoxy,

with the proviso that the 2-aminotetraline excludes (a) $R=R_1=CH_3O$ or OH, $R_2=H$,

(b)
$$R=F$$
, $R_1=CH_3O$ or OH , $R_2=H$, (c) $R_1=-OCH_3$, $R=CH_3$ and $R_2=H$, or (d)

 $R=R_1=R_2=CH_3O$, and

X is the monovalent anion of a pharmacologically acceptable acid.

- 10. Canceled.
- 11.-12. Canceled.
- 13. Canceled.
- 14. (Previously Presented) A method of treating an inflammatory and/or autoimmune pathology induced by inflammatory cytokines, which method comprises administering to a patent in need of same an effective amount of a compound selected from the group consisting of:
 - S(-)-2-amino-6-fluoro-7-hydroxytetraline hydrochloride;
 - R(+)-2-amino-6-fluoro-7-hydroxytetraline hydrochloride;
 - (R,S)-2-amino-5,6-difluoro-7-methoxytetraline hydrochloride;
 - (R,S)-2-amino-6-fluoro-7-methyltetraline hydrochloride;
 - (R,S)-2-amino-7-fluoro-6-hydroxytetraline hydrochloride;
 - (R,S)-7-acetyl-2-amino-6-methyltetraline hydrochloride; and

FANTO et al Appl. No. 09/816,317 June 24, 2004

- (R,S)-2-amino-7-fluoro-6-methoxytetraline hydrochloride.
- 15. (Previously Presented) A method of preventing or treating septic shock comprising administering to a patient in need of same an effective amount of a compound selected from the group consisting of:
 - S(-)-2-amino-6-fluoro-7-hydroxytetraline hydrochloride;
 - R(+)-2-amino-6-fluoro-7-hydroxytetraline hydrochloride;
 - (R,S)-2-amino-5,6-difluoro-7-methoxytetraline hydrochloride;
 - (R,S)-2-amino-6-fluoro-7-methyltetraline hydrochloride;
 - (R,S)-2-amino-7-fluoro-6-hydroxytetraline hydrochloride;
 - (R,S)-7-acetyl-2-amino-6-methyltetraline hydrochloride; and
 - (R,S)-2-amino-7-fluoro-6-methoxytetraline hydrochloride.
 - 16. Canceled.